{"id":18131,"date":"2025-08-27T15:45:00","date_gmt":"2025-08-27T14:45:00","guid":{"rendered":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/?p=18131"},"modified":"2025-09-05T15:15:19","modified_gmt":"2025-09-05T14:15:19","slug":"life-reimagined-the-biotech-revolution-and-longevity","status":"publish","type":"post","link":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity","title":{"rendered":"Life reimagined: The biotech revolution and longevity"},"content":{"rendered":"\n<div class=\"well b-blue-tint-4 mb-3\">\n      <h2 class=\"h5\">Key points<\/h2>\n      <ul class=\"list-spaced\">\n        <li>\n          Cancer vaccines are being developed to target unique markers on cancer\n          cells, with promising results in clinical trials.\n        <\/li>\n        <li>\n          Researchers are exploring various approaches to combat Alzheimer\u2019s,\n          including targeting proteins in the brain, investigating potential\n          viral infections, and developing diagnostic tools.\n        <\/li>\n        <li>\n          GLP\u20111 drugs, originally developed for diabetes, are being explored for\n          a wide range of conditions, including obesity, cardiovascular disease,\n          and neurodegenerative diseases, with potential to reduce inflammation\n          and improve cellular health.\n        <\/li>\n        <li>\n          The unstoppable trend of the ageing of populations around the world\n          provides a powerful backdrop for investments in biotech and beyond.\n        <\/li>\n      <\/ul>\n    <\/div>\n    <p>\n      The quest for better health and enhanced quality of life has brought\n      biotechnology to the forefront of health care as it drives innovative\n      medical solutions. Our June 2024 article\n      <a\n        href=\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/longevity-cracking-the-ageing-code\"\n        title=\"Longevity: cracking the ageing code\"\n      >\n        Longevity: Cracking the ageing code\n      <\/a>\n      noted that while we are optimistic about the development of cutting-edge\n      methods to combat the effects of ageing, one way to improve healthspans,\n      or the number of healthy years before the end of life, is to tackle the\n      diseases of old age.\n    <\/p>\n    <p>\n      As we continue to examine this theme, we survey the growing number of\n      medical innovations that could revolutionise the battle against two major\n      age-related challenges \u2013 cancer and Alzheimer\u2019s \u2013 and explore how drugs\n      designed for obesity may end up treating a much wider range of health\n      issues, some of which become more prevalent with age. We also look at ways\n      to position portfolios for the ageing theme through biotech investments\n      and beyond.\n    <\/p>\n    <!-- SECTION -->\n    <h2>The contour of a cancer cure?<\/h2>\n    <p>\n      Cancer is the second-leading cause of death among the elderly. Recent\n      scientific advancements have accelerated the development of cancer\n      vaccines, which could make them an increasingly viable approach in cancer\n      treatment.\n    <\/p>\n    <!-- EXHIBIT 1 -->\n    <h3>Cardiovascular diseases, cancer, and Alzheimer\u2019s in the lead<\/h3>\n    <h4>Leading causes of death for Canadians aged 85 and older (2023)<\/h4>\n    <div class=\"row mb-4\">\n      <div class=\"col-lg-10 col-md-8 col-sm-8 col-xs-10 col-xxs-12\">\n        <img decoding=\"async\"\n          src=\"https:\/\/www.rbcwealthmanagement.com\/assets\/wp-content\/uploads\/global\/life-reimagined-longevity-en-chart-1.png\"\n          alt=\"Leading causes of death for Canadians aged 85 and older (2023)\"\n          class=\"img-fluid mb-1-half\"\n          aria-describedby=\"chart1desc\"\n        \/>\n        <p class=\"sr-only\" id=\"chart1desc\">\n          The pie chart shows the leading causes of death for Canadians aged 85\n          and older in 2023. Diseases of the heart were the leading cause of\n          death, accounting for 21.5% of total deaths, followed by cancer\n          (15.5%), respiratory diseases (6.2%), strokes and aneurysms (5.4%),\n          accidents (5.1%), COVID-19 (3.6%), and Alzheimer&#8217;s disease (2.9%).\n        <\/p>\n        <p class=\"footnote\">\n          Note: Leading causes of death among the elderly population are similar\n          in most developed countries.\n        <\/p>\n        <p class=\"disclaimer\">\n          Source &#8211; RBC Wealth Management, Statistics Canada\n        <\/p>\n      <\/div>\n    <\/div>\n    <!-- SUB -->\n    <h3>Cancer vaccines<\/h3>\n    <p>\n      Most traditional antiviral vaccines work by introducing small, specific\n      components of an infectious organism \u2013 referred to as antigens \u2013 into the\n      immune system. The aim is to induce an immune response and establish a\n      \u201cmemory\u201d so that future contact with a real pathogen is quickly addressed\n      as the body easily recognises an infectious agent as being foreign.\n    <\/p>\n    <p>\n      Cancer, however, represents a unique challenge, as it originates from a\n      body\u2019s own cells, making it difficult for the immune system to recognise\n      the cancer as foreign. The realisation some 20&nbsp;years ago that many cancer\n      cells are covered with unique antigens, known as \u201cneoantigens,\u201d was a\n      breakthrough. Neoantigens are not typically found in the human body and\n      usually arise through genetic mutations within cancer cells. Neoantigens\n      hold promise for cancer therapy as they can be targeted by the immune\n      system.\n    <\/p>\n    <p>\n      Cancer vaccines introduce neoantigens directly into the body, training the\n      immune system to recognise them as foreign and target any cancer cells\n      that carry them. In 2024, The Lancet, a medical journal, reported that a\n      human trial had shown promising potential by using an mRNA, or messenger\n      RNA, molecule to trigger the production of neoantigens that marked\n      melanoma skin cancer for the immune system to attack. Three years after\n      treatment in the trial, the risk of cancer recurrence or death fell by\n      close to half, a promising result.\n    <\/p>\n    <p>\n      mRNA vaccines are best known as the technology used to change the course\n      of the COVID-19 pandemic. Though it seemed to have appeared at that time\n      out of nowhere, the technology has been researched for more than 40 years.\n      The mRNA molecule carries genetic material including instructions for\n      producing proteins in cells. These proteins can help train the immune\n      system to recognise a virus as an invader, enabling the body to identify\n      and attack it in the future.\n    <\/p>\n    <!-- SUB -->\n    <h3>Personalised cancer vaccines<\/h3>\n    <p>\n      Advances in mRNA technology have spearheaded the idea of personalised\n      cancer vaccines tailored to a patient\u2019s specific mutations. After a\n      biopsy, the tumour is profiled, and mutations likely to generate proteins\n      that can be recognised by the immune system are identified. An mRNA\n      vaccine can then be developed that targets the neoantigens produced by\n      these mutations.\n    <\/p>\n    <p>\n      Using artificial intelligence, which can predict the molecular markers\n      most likely to stimulate the immune system into action, it\u2019s been\n      demonstrated that a vaccine can be produced in less than two months. In\n      the KEYNOTE-942 trial, Moderna\u2019s personalised mRNA vaccine was developed\n      in just six weeks from biopsy to patient administration.\n    <\/p>\n    <p>\n      But if the process is quick, it is also very expensive, costing up to\n      several hundred thousand dollars. Scientists are looking to develop\n      off-the-shelf vaccines that can work in large populations by targeting\n      common tumours. They are also exploring the potential use of cancer\n      vaccines as an adjuvant \u2013 or booster \u2013 in combination with other\n      immunotherapies.\n    <\/p>\n    <p>\n      Cancer vaccines are different from traditional vaccines as they aim to\n      cure, rather than prevent, a disease. There are more than 600 ongoing\n      clinical trials for cancer vaccines, according to ClinicalTrials.gov, a\n      registry managed by the U.S. National Library of Medicine that tracks\n      clinical trials conducted in more than 200 countries. These trials are\n      targeting a wide range of cancers, including those found in the skin,\n      ovaries, brain, and lungs.\n    <\/p>\n    <p>\n      Though much work remains to be done, cancer vaccines may well one day have\n      progressed enough that they can lessen the reliance on more invasive\n      treatments like chemotherapy and surgery for large numbers of patients.\n    <\/p>\n    <!-- SECTION -->\n    <h2>Encouraging progress for Alzheimer\u2019s<\/h2>\n    <p>\n      By the age of 85, the probability of a person developing this devastating\n      disease is currently one in three, according to the U.S. National\n      Institute on Aging. A remorselessly neurodegenerative condition,\n      Alzheimer\u2019s leads to a gradual loss of memory and thinking skills.\n      According to a study in The Lancet, the number of people with dementia, of\n      which Alzheimer\u2019s is the leading cause, is projected to rise from 57&nbsp;million in 2019 to 153&nbsp;million in 2050.\n    <\/p>\n    <p>\n      Progress in finding treatments has been slow, partly because the root\n      cause of the disease has been difficult to identify.\n    <\/p>\n    <p>\n      Many scientists believe that Alzheimer\u2019s is most likely caused by an\n      abnormal buildup of beta-amyloid proteins in the brain, forming plaques\n      that trigger the formation of tangled clumps of another protein, tau. What\n      initiates this process remains unclear, but researchers believe these\n      developments lead to neuron dysfunction and eventual death.\n    <\/p>\n    <!-- EXHIBIT 2 -->\n    <h3>A one-way trend<\/h3>\n    <h4>All-age number of people with dementia worldwide (millions)<\/h4>\n    <div class=\"row mb-4\">\n      <div class=\"col-lg-10 col-md-8 col-sm-8 col-xs-10 col-xxs-12\">\n        <img decoding=\"async\"\n          src=\"https:\/\/www.rbcwealthmanagement.com\/assets\/wp-content\/uploads\/global\/life-reimagined-longevity-en-chart-2.png\"\n          alt=\"All-age number of people with dementia worldwide (millions)\"\n          class=\"img-fluid mb-1-half\"\n          aria-describedby=\"chart2desc\"\n        \/>\n        <p class=\"sr-only\" id=\"chart2desc\">\n          The graph depicts the numbers of individuals with Alzheimer\u2019s\n          worldwide, both males and females, from 1990 to 2019 and the projected\n          numbers to 2050. The base-case scenario is shown accompanied by an\n          optimistic and a pessimistic scenario. In 1990, there were some 14\n          million females with Alzheimer\u2019s. The number increased to 33 million\n          in 2019 and is expected to reach 98 million in 2050. In the optimistic\n          scenario, only 78 million females would contract the disease in 2050,\n          while in the pessimistic scenario as many as 121 million could be\n          afflicted. As for the male population, in 1990, there were some 8\n          million with Alzheimer\u2019s. The number swelled to 19 million in 2019 and\n          is expected to reach 53 million in 2050. In the optimistic scenario,\n          only 44 million males would contract the disease worldwide in 2050,\n          though in the pessimistic scenario as many as 62 million could be\n          afflicted.\n        <\/p>\n        <ul class=\"rbc-legend rbc-legend-inline\">\n          <li class=\"rbc-legend-item\">\n            <div class=\"rbc-legend-line c-warm-yellow\"><\/div>\n            Women\n          <\/li>\n          <li class=\"rbc-legend-item\">\n            <div class=\"rbc-legend-line c-seaweed\"><\/div>\n            Men\n          <\/li>\n        <\/ul>\n        <p class=\"footnote\">\n          Notes: Estimated trends in global all-age number of cases, with 95%\n          uncertainty intervals, 2019\u20132050; the solid line is the predicted\n          change in the number of cases over time, based on statistical\n          modeling. The shaded areas around the solid line represent the 95%\n          uncertainty interval, meaning there is a 95% probability that the true\n          estimate of the trend in all-age number of cases lies in the shaded\n          areas.\n        <\/p>\n        <p class=\"footnote\">\n          Study by the Global Burden of Disease (GBD) 2019 Dementia Forecasting\n          Collaborators. GBD is a globally recognised research initiative led by\n          the Institute for Health Metrics and Evaluation at the University of\n          Washington. This study was funded by the Bill &amp; Melinda Gates\n          Foundation and Gates Ventures. It was corroborated by a July 2025\n          study in BMC Medicine, \u201cTrend analysis and future predictions of\n          global burden of Alzheimer\u2019s disease and other dementias: a study\n          based on the global burden of disease database from 1990 to 2021\u201d (Hao\n          &amp; Chen).\n        <\/p>\n        <p class=\"disclaimer\">Source &#8211; The Lancet, Public Health 2022<\/p>\n      <\/div>\n    <\/div>\n    <p>\n      Scientists thus focused on targeting amyloid proteins and developed\n      lecanemab and donanemab, two drugs approved by the U.S. Food and Drug\n      Administration in 2023 for patients with mild cognitive impairment. These\n      treatments are designed to artificially produce antibodies, or specialised\n      blood proteins, to counter beta-amyloid proteins. The drugs work by\n      flooding the bloodstream with antibodies that bind to the beta-amyloid\n      plaques, prompting immune cells to clear them away. According to The\n      Pharmaceutical Journal, the drugs have been shown to slow the progress of\n      cognitive decline by up to 35&nbsp;percent.\n    <\/p>\n    <p>\n      However, the therapies are not without limitations, and there are ongoing\n      concerns regarding their effectiveness, practicality, and safety. Though\n      they may slow the progression of Alzheimer\u2019s, these drugs do not halt or\n      reverse it, and they must be administered biweekly via intravenous\n      infusion as they break down quickly in the body. The regimen also requires\n      frequent MRI scans to monitor for serious side effects \u2013 such as brain\n      swelling and bleeding. These drawbacks, as well as the high overall\n      treatment cost, limit the accessibility of these drugs for widespread use.\n    <\/p>\n    <p>\n      Today, a growing number in the scientific community are contending that\n      plaques and tangles are not the cause of Alzheimer\u2019s but rather the body\u2019s\n      response to an underlying viral infection. This theory builds on the\n      discovery that viruses can trigger neurological diseases, much like how\n      the SARS\u2011CoV\u20112 virus (the cause of COVID\u201119) is linked to neurological\n      symptoms and complications, or how the Epstein-Barr virus is linked to\n      multiple sclerosis. If such a link can be established with certainty, then\n      eliminating a virus through vaccination or antiviral drugs could offer a\n      path to disease prevention or treatment. Clinical trials are ongoing to\n      test the efficacy of antiviral drugs.\n    <\/p>\n    <p>\n      Scientists are also exploring a blood test designed to recognise traces of\n      abnormal tangles of tau proteins up to two decades before Alzheimer\u2019s\n      symptoms appear. Poor diagnosis is currently a challenge, with less than\n      five percent of patients in the UK receiving an accurate Alzheimer\u2019s\n      diagnosis through PET scans or lumbar punctures, according to Alzheimer\u2019s\n      Research UK. Early diagnosis is crucial for accessing appropriate care and\n      enabling the use of current and future treatments.\n    <\/p>\n    <p>\n      While current treatments for Alzheimer\u2019s may offer limited comfort to\n      those already afflicted with the disease, they are an important step\n      forward. Like many first-generation therapies, they lay the foundation for\n      future innovations, raising hope that, in time, the burden of the disease\n      may be eased for the next generation.\n    <\/p>\n    <!-- SECTION -->\n    <h2>GLP\u20111: The wonder drugs?<\/h2>\n    <p>\n      Originally developed for type 2 diabetes, glucagon-like peptide 1, or\n      GLP\u20111, drugs gained widespread recognition in 2021 for their effectiveness\n      in treating obesity. Obesity remains a major public health challenge in\n      most of the Western world. In the U.S., over 39&nbsp;percent of adults are\n      considered obese and suffer from various related conditions including\n      heart disease, diabetes, and certain cancers, per data from the Centers\n      for Disease Control and Prevention.\n    <\/p>\n    <p>\n      GLP\u20111 drugs are synthetic versions of a natural gut hormone that helps\n      control the levels of sugar in the blood by triggering insulin release and\n      slowing digestion. They are receptor agonist medications, meaning they\n      trigger a physiological response when they bind to a receptor.\n    <\/p>\n    <p>\n      Beyond diabetes and obesity, GLP\u20111 drugs are being studied as potential\n      treatments for an unprecedentedly wide range of other medical conditions\n      that goes far beyond pharma companies\u2019 usual search for new markets for\n      their drugs.\n    <\/p>\n    <p>\n      In fact, in March 2024, semaglutide, a GLP\u20111 drug sold as Ozempic for\n      diabetes and Wegovy for weight loss, was approved in the U.S. for\n      cardiovascular disease in overweight patients. How can a drug that was\n      originally developed for diabetes help treat heart disease? Because it\n      interacts with GLP\u20111 receptors found on blood vessels and heart cells,\n      potentially reducing the risk of strokes and heart attacks. These\n      cardiovascular benefits seem to be independent of weight loss.\n    <\/p>\n    <p>\n      Trials are also ongoing to assess whether GLP\u20111 drugs could be used to\n      treat chronic kidney and liver disease, delay the onset of\n      neurodegenerative diseases such as Alzheimer\u2019s and Parkinson\u2019s, treat\n      substance abuse and addictions, and combat conditions characterised by\n      inflammation such as atherosclerosis.\n    <\/p>\n    <p>\n      One reason for optimism is that GLP\u20111 drugs seem to support cellular\n      health. When cells with GLP\u20111 receptors become damaged or dysfunctional,\n      treatment with GLP\u20111 drugs seems to help them recover. These drugs may\n      thus be able to reduce inflammation throughout the body, and since\n      inflammation is thought to be\n      <a\n        href=\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/longevity-cracking-the-ageing-code\"\n        title=\"Longevity: cracking the ageing code\"\n        >a key trigger of many diseases<\/a\n      >, the potential benefits of GLP\u20111 drugs could extend beyond current uses.\n    <\/p>\n    <p>\n      Optimism needs to be tempered as challenging hurdles remain \u2013 just because a\n      drug shows potential in treating a condition does not mean it will become\n      an approved treatment. Moreover, it may turn out to not be as effective as\n      existing medications on the market, or the price of the drug could limit\n      its uptake.\n    <\/p>\n    <p>\n      GLP\u20111 drugs are expensive \u2013 some have out-of-pocket costs reaching $16,000\n      per year in the U.S. \u2013 though prices vary internationally. Innovation could\n      help reduce the cost of these drugs, such as developing a pill version to\n      replace current injectables \u2013 a breakthrough that many researchers in the\n      field think may be possible within the next two years. Additionally,\n      patent expirations outside the West in less than a decade should encourage\n      the production of more affordable generic versions.\n    <\/p>\n    <!-- BOX -->\n    <div class=\"well b-blue-tint-4 my-3\">\n      <h3>Cut, paste, cure: The CRISPR revolution<\/h3>\n      <p>\n        Another medical innovation worth mentioning, CRISPR (Clustered Regularly\n        Interspaced Short Palindromic Repeats) gene editing, also appears to\n        hold great promise. CRISPR is a tool that enables scientists to\n        precisely edit DNA, much like cutting and pasting text in a document. It\n        can repair faulty genes and treat diseases by making targeted changes to\n        the genetic code. The first CRISPR gene editing treatment for sickle\n        cell disease, a genetic disorder, was approved in the U.S. in 2023. The\n        technology could potentially be used to develop cures for a wide range\n        of conditions from cancer to high cholesterol. For cancer, the treatment\n        would involve removing immune cells from a patient, editing them to\n        enable the cells to attack the disease more powerfully, and then\n        reintroducing them into the body.\n      <\/p>\n    <\/div>\n    <!-- SECTION -->\n    <h2>Biotech and beyond<\/h2>\n    <p>\n      <strong>Biotech<\/strong> is the obvious sector through which to invest in\n      the theme of combatting ageing. Biotech companies are often perceived by\n      investors as the research pipeline of Big Pharma. With ample cash on their\n      balance sheets and over $350&nbsp;billion in annual pharmaceutical sales at\n      risk over the next decade due to patent expirations, RBC Capital Markets\n      expects pharmaceutical companies\u2019 merger and acquisition (M&amp;A)\n      activity to pick up, bolstered by a more permissive Federal Trade\n      Commission in the U.S.\n    <\/p>\n    <p>\n      The Trump administration\u2019s unconventional choice of Robert F. Kennedy Jr.\n      as Secretary of Health and Human Services raises some uncertainties for\n      the biotech industry. Despite these, RBC Capital Markets analysts perceive\n      the industry\u2019s fundamentals, including robust pricing power, as positive.\n      They also think commercial-stage companies that are undervalued and\n      potential M&amp;A targets, or those with underappreciated upside\n      catalysts, look like the most interesting opportunities.\n    <\/p>\n    <p>\n      <strong>Medtech<\/strong> is another industry with a focus on developing\n      innovative medical solutions to address age-related health issues.\n      Innovations in patient treatments and delivery methods are being driven by\n      increased demand from an ageing population. Many growth areas remain\n      underpenetrated with significant market share up for grabs, in RBC Capital\n      Markets\u2019 view. For example, innovations in robotic surgery are making\n      treatments safer and minimally invasive, with faster patient recovery\n      times. The market share of surgical robotics is currently low from a\n      global perspective, but it is not inconceivable that robot-assisted\n      surgeries will become the norm within 10 to 15 years, according to Nature\n      Medicine.\n    <\/p>\n    <p>\n      Other industries may also experience shifts in demand as the population\n      ages and play into the theme as well:\n    <\/p>\n    <p>\n      <strong>Insurance and wealth management companies<\/strong> may well find\n      they have an attentive audience as individuals will need to consider how\n      not to outlive their savings.\n    <\/p>\n    <p>\n      <strong>Homebuilders<\/strong> in various geographies may experience\n      changing demand for residential space. Housing demand to accommodate\n      multi-generational households may rise in some regions, while others may\n      see growing demand for single-occupancy homes.\n    <\/p>\n    <p>\n      <strong>Select Industrials<\/strong> may harness their ingenuity to develop\n      innovations designed to help the elderly. For instance, Japanese engineers\n      have developed a floor firm enough for use by wheelchairs that also has\n      shock-absorbing properties. As a result, the fall impact is reduced by\n      half versus a conventional floor, according to the manufacturer. The\n      innovative floor is currently being used in a growing number of medical\n      institutions and nursing homes in Japan to help prevent fractures caused\n      by falls \u2013 the leading cause of death among the elderly.\n    <\/p>\n    <p>\n      The prospects for positive healthspan outcomes appear more promising today\n      than 20 years ago, driven by a surge in innovation from biotech and\n      medtech companies. At the same time, industrial sectors such as\n      homebuilders are developing solutions to make the later stages of life\n      more comfortable and secure. We believe these sectors present compelling\n      long-term opportunities for investors as the aged population grows.\n    <\/p>\n","protected":false},"excerpt":{"rendered":"<p>There\u2019s more to a long life than simply a long lifespan. The number of years we spend in good health, or healthspan, is key. With biotech spurring promising medical innovations, we look at how it can fit into investment portfolios.<\/p>\n","protected":false},"author":15,"featured_media":18132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"rbcwm_post_date":"2025-08-27T13:09:00","editor_notices":[],"rbc_url_alias":"","rbcwm_featured_desktop_image_position":"","rbcwm_featured_mobile_image_position":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[80],"tags":[721,715,716,718,720,719,717,722],"rbcwm_content_owner":[506],"rbcwm_need":[],"rbcwm_segment":[],"rbcwm_solution":[],"rbcwm_topic":[81],"rbcwm_channel":[],"rbcwm_format":[],"class_list":["post-18131","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","tag-alzheimers-progress","tag-biotech","tag-biotechnology","tag-cancer-vaccines","tag-cellular-health","tag-cellular-vaccines","tag-longevity","tag-medtech","rbcwm_content_owner-pag","rbcwm_topic-global-insights"],"acf":{"rbcwm_subtitle":"There\u2019s more to a long life than simply a long lifespan. The number of years we spend in good health, or healthspan, is key. With biotech spurring promising medical innovations, we look at how it can fit into investment portfolios.","rbcwm_post_author":[963],"rbcwm_custom_breadcrumb_text":"","rbcwm_custom_breadcrumb_link_url":"","rbcwm_disclaimers":{"add_disclosures":["Yes"],"perspective_disclaimer":"","expandable":"","omit_from_pages":"","disclaimer_footnote":""},"rbcwm_insight_cta_id":[8231],"rbcwm_pagination":{"next_link":"","next_link_text":"Next article","previous_link":"","previous_link_text":"Previous article"},"rbcwm_video_duration":"","article_time":"","rbcwm_enable_toc":false,"rbcwm_toc_selector":"h2"},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v26.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Life reimagined: The biotech revolution and longevity<\/title>\n<meta name=\"description\" content=\"There\u2019s more to a long life than simply a long lifespan. The number of years we spend in good health, or healthspan, is key. With biotech spurring promising medical innovations, we look at how it can fit into investment portfolios.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Life reimagined: The biotech revolution and longevity\" \/>\n<meta property=\"og:description\" content=\"There\u2019s more to a long life than simply a long lifespan. The number of years we spend in good health, or healthspan, is key. With biotech spurring promising medical innovations, we look at how it can fit into investment portfolios.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity\" \/>\n<meta property=\"og:site_name\" content=\"RBC Wealth Management\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-27T14:45:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-05T14:15:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2023\/02\/scl-happy-grandfather-and-granddaughter-hor-EU.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"taravandenberg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity\"},\"author\":{\"name\":\"taravandenberg\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/person\/8803578712bd073b70bbc17e6909b59b\"},\"headline\":\"Life reimagined: The biotech revolution and longevity\",\"datePublished\":\"2025-08-27T14:45:00+00:00\",\"dateModified\":\"2025-09-05T14:15:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity\"},\"wordCount\":2895,\"publisher\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2025\/08\/happy-grandfather-and-granddaughter.jpg\",\"keywords\":[\"alzheimer's progress\",\"biotech\",\"biotechnology\",\"cancer vaccines\",\"cellular health\",\"cellular vaccines\",\"longevity\",\"medtech\"],\"articleSection\":[\"Analysis\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity\",\"url\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity\",\"name\":\"Life reimagined: The biotech revolution and longevity\",\"isPartOf\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2025\/08\/happy-grandfather-and-granddaughter.jpg\",\"datePublished\":\"2025-08-27T14:45:00+00:00\",\"dateModified\":\"2025-09-05T14:15:19+00:00\",\"description\":\"There\u2019s more to a long life than simply a long lifespan. The number of years we spend in good health, or healthspan, is key. With biotech spurring promising medical innovations, we look at how it can fit into investment portfolios.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#primaryimage\",\"url\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2025\/08\/happy-grandfather-and-granddaughter.jpg\",\"contentUrl\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2025\/08\/happy-grandfather-and-granddaughter.jpg\",\"width\":3210,\"height\":2140,\"caption\":\"happy grandfather and granddaughter hugging while sitting on a beige couch\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Life reimagined: The biotech revolution and longevity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#website\",\"url\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/\",\"name\":\"RBC Wealth Management\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#organization\",\"name\":\"RBC Wealth Management\",\"alternateName\":\"RBC Wealth Management\",\"url\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2023\/02\/rbc.png\",\"contentUrl\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2023\/02\/rbc.png\",\"width\":3000,\"height\":2000,\"caption\":\"RBC Wealth Management\"},\"image\":{\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/person\/8803578712bd073b70bbc17e6909b59b\",\"name\":\"taravandenberg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/807f9a5b689d28ecee3262e00b8755e7d4849ada61e3144de1a2d65c713bfc12?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/807f9a5b689d28ecee3262e00b8755e7d4849ada61e3144de1a2d65c713bfc12?s=96&d=mm&r=g\",\"caption\":\"taravandenberg\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Life reimagined: The biotech revolution and longevity","description":"There\u2019s more to a long life than simply a long lifespan. The number of years we spend in good health, or healthspan, is key. With biotech spurring promising medical innovations, we look at how it can fit into investment portfolios.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity","og_locale":"en_GB","og_type":"article","og_title":"Life reimagined: The biotech revolution and longevity","og_description":"There\u2019s more to a long life than simply a long lifespan. The number of years we spend in good health, or healthspan, is key. With biotech spurring promising medical innovations, we look at how it can fit into investment portfolios.","og_url":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity","og_site_name":"RBC Wealth Management","article_published_time":"2025-08-27T14:45:00+00:00","article_modified_time":"2025-09-05T14:15:19+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2023\/02\/scl-happy-grandfather-and-granddaughter-hor-EU.jpg","type":"image\/jpeg"}],"author":"taravandenberg","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#article","isPartOf":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity"},"author":{"name":"taravandenberg","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/person\/8803578712bd073b70bbc17e6909b59b"},"headline":"Life reimagined: The biotech revolution and longevity","datePublished":"2025-08-27T14:45:00+00:00","dateModified":"2025-09-05T14:15:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity"},"wordCount":2895,"publisher":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#organization"},"image":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#primaryimage"},"thumbnailUrl":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2025\/08\/happy-grandfather-and-granddaughter.jpg","keywords":["alzheimer's progress","biotech","biotechnology","cancer vaccines","cellular health","cellular vaccines","longevity","medtech"],"articleSection":["Analysis"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity","url":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity","name":"Life reimagined: The biotech revolution and longevity","isPartOf":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#primaryimage"},"image":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#primaryimage"},"thumbnailUrl":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2025\/08\/happy-grandfather-and-granddaughter.jpg","datePublished":"2025-08-27T14:45:00+00:00","dateModified":"2025-09-05T14:15:19+00:00","description":"There\u2019s more to a long life than simply a long lifespan. The number of years we spend in good health, or healthspan, is key. With biotech spurring promising medical innovations, we look at how it can fit into investment portfolios.","breadcrumb":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#primaryimage","url":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2025\/08\/happy-grandfather-and-granddaughter.jpg","contentUrl":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2025\/08\/happy-grandfather-and-granddaughter.jpg","width":3210,"height":2140,"caption":"happy grandfather and granddaughter hugging while sitting on a beige couch"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/insights\/life-reimagined-the-biotech-revolution-and-longevity#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/"},{"@type":"ListItem","position":2,"name":"Life reimagined: The biotech revolution and longevity"}]},{"@type":"WebSite","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#website","url":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/","name":"RBC Wealth Management","description":"","publisher":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#organization","name":"RBC Wealth Management","alternateName":"RBC Wealth Management","url":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2023\/02\/rbc.png","contentUrl":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2023\/02\/rbc.png","width":3000,"height":2000,"caption":"RBC Wealth Management"},"image":{"@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/person\/8803578712bd073b70bbc17e6909b59b","name":"taravandenberg","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/807f9a5b689d28ecee3262e00b8755e7d4849ada61e3144de1a2d65c713bfc12?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/807f9a5b689d28ecee3262e00b8755e7d4849ada61e3144de1a2d65c713bfc12?s=96&d=mm&r=g","caption":"taravandenberg"}}]}},"jetpack_featured_media_url":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-content\/uploads\/sites\/9\/2025\/08\/happy-grandfather-and-granddaughter.jpg","jetpack_sharing_enabled":true,"publishpress_future_action":{"enabled":false,"date":"2026-04-13 04:44:11","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"RBC Wealth Management","distributor_original_site_url":"https:\/\/www.rbcwealthmanagement.com\/en-eu","push-errors":false,"last_revision_date":"2025-09-05 15:15:17","_links":{"self":[{"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/posts\/18131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/comments?post=18131"}],"version-history":[{"count":6,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/posts\/18131\/revisions"}],"predecessor-version":[{"id":18220,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/posts\/18131\/revisions\/18220"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/rbcwm_cta\/8231"},{"embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/rbcwm_people\/963"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/media\/18132"}],"wp:attachment":[{"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/media?parent=18131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/categories?post=18131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/tags?post=18131"},{"taxonomy":"rbcwm_content_owner","embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/rbcwm_content_owner?post=18131"},{"taxonomy":"rbcwm_need","embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/rbcwm_need?post=18131"},{"taxonomy":"rbcwm_segment","embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/rbcwm_segment?post=18131"},{"taxonomy":"rbcwm_solution","embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/rbcwm_solution?post=18131"},{"taxonomy":"rbcwm_topic","embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/rbcwm_topic?post=18131"},{"taxonomy":"rbcwm_channel","embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/rbcwm_channel?post=18131"},{"taxonomy":"rbcwm_format","embeddable":true,"href":"https:\/\/www.rbcwealthmanagement.com\/en-eu\/wp-json\/wp\/v2\/rbcwm_format?post=18131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}